Prognosis
Endo’s Patent Loss Over Blood Pressure Drug Adds to Its Troubles
- Embattled by opioid suits, Endo now dealt blow over bestseller
- Generics will leave Endo ‘little residual value,’ analyst says
This article is for subscribers only.
Endo International Plc’s loss in a patent fight over its bestselling blood pressure drug comes at a tough time for the company, as it grapples with opioid lawsuits and weighs a debt restructuring.
Endo’s Par Pharmaceutical lost a trial court ruling Tuesday in its bid to stop Eagle Pharmaceuticals Inc. from selling a generic version of Vasostrict, used to treat low blood pressure. Eagle’s version of the drug won’t infringe two Par patents, U.S. District Judge Colm Connolly in Wilmington, Delaware, said in his opinion, after a three-day trial without a jury in July.